AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review

Go back to AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review

AstraZeneca (AZN) Halted, News Pending

December 9, 2016 9:54 AM EST

AstraZeneca (NYSE: AZN) Halted, News Pending

... More